<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33361387</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2332-7812</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title><ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation></Journal><ArticleTitle>TDP-43-specific Autoantibody Decline in Patients With Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e937</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000000937</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We hypothesize alterations in the quality and quantity of anti-43-kDa TAR DNA-binding protein (TDP-43) naturally occurring autoantibodies (NAbs) in patients with amyotrophic lateral sclerosis (ALS); therefore, we assessed relative binding properties of anti-TDP-43 NAbs composite in plasma from patients with ALS in comparison with healthy individuals.</AbstractText><AbstractText Label="METHODS">ELISA competition assay was used to explore the apparent avidity/affinity of anti-TDP-43 NAbs in plasma from 51 normal controls and 30 patients with ALS. Furthermore, the relative levels of anti-TDP-43 NAbs within the immunoglobulin (Ig) classes of IgG (isotype IgG1-4) and IgMs were measured using classical indirect ELISA. The occurring results were hereafter correlated with the measures of disease duration and disease progression.</AbstractText><AbstractText Label="RESULTS">High-avidity/affinity anti-TDP-43 NAbs levels were significantly reduced in plasma samples from patients with ALS. In addition, a significant decrease in relative levels of anti-TDP-43 IgG3 and IgM NAbs and a significant increase in anti-TDP-43 IgG4 NAbs were observed in ALS plasma vs controls. Furthermore, a decrease in global IgM and an increase in IgG4 levels were observed in ALS. These aberrations of humoral immunity correlated with disease duration, but did not correlate with ALS Functional Rating Scale-Revised scores.</AbstractText><AbstractText Label="CONCLUSIONS">Our results may suggest TDP-43-specific immune aberrations in patients with ALS. The skewed immune profiles observed in patients with ALS could indicate a deficiency in the clearance capacity and/or blocking of TDP-43 transmission and propagation. The decrease in levels of high affinity/avidity anti-TDP-43 NAbs and IgMs correlates with disease progression and may be disease predictors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Anne Kallehauge</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>From the Research Laboratory for Stereology and Neuroscience (A.K.N., J.F., S.O., B.P., S.A., T.B.), and Department of Neurology (K.S., K.W.), Bispebjerg-Frederiksberg Hospital, University Hospital of Copenhagen; Neuromuscular Clinic (K.S.), Department of Neurology, Rigshospitalet, Copenhagen; Institute of Clinical Medicine (B.P.), Faculty of Health and Medical Sciences, University of Copenhagen; and Copenhagen Center for Translational Research (S.A., T.B.), Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Folke</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Research Laboratory for Stereology and Neuroscience (A.K.N., J.F., S.O., B.P., S.A., T.B.), and Department of Neurology (K.S., K.W.), Bispebjerg-Frederiksberg Hospital, University Hospital of Copenhagen; Neuromuscular Clinic (K.S.), Department of Neurology, Rigshospitalet, Copenhagen; Institute of Clinical Medicine (B.P.), Faculty of Health and Medical Sciences, University of Copenhagen; and Copenhagen Center for Translational Research (S.A., T.B.), Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owczarek</LastName><ForeName>Sylwia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Research Laboratory for Stereology and Neuroscience (A.K.N., J.F., S.O., B.P., S.A., T.B.), and Department of Neurology (K.S., K.W.), Bispebjerg-Frederiksberg Hospital, University Hospital of Copenhagen; Neuromuscular Clinic (K.S.), Department of Neurology, Rigshospitalet, Copenhagen; Institute of Clinical Medicine (B.P.), Faculty of Health and Medical Sciences, University of Copenhagen; and Copenhagen Center for Translational Research (S.A., T.B.), Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svenstrup</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Research Laboratory for Stereology and Neuroscience (A.K.N., J.F., S.O., B.P., S.A., T.B.), and Department of Neurology (K.S., K.W.), Bispebjerg-Frederiksberg Hospital, University Hospital of Copenhagen; Neuromuscular Clinic (K.S.), Department of Neurology, Rigshospitalet, Copenhagen; Institute of Clinical Medicine (B.P.), Faculty of Health and Medical Sciences, University of Copenhagen; and Copenhagen Center for Translational Research (S.A., T.B.), Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winge</LastName><ForeName>Kristian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Research Laboratory for Stereology and Neuroscience (A.K.N., J.F., S.O., B.P., S.A., T.B.), and Department of Neurology (K.S., K.W.), Bispebjerg-Frederiksberg Hospital, University Hospital of Copenhagen; Neuromuscular Clinic (K.S.), Department of Neurology, Rigshospitalet, Copenhagen; Institute of Clinical Medicine (B.P.), Faculty of Health and Medical Sciences, University of Copenhagen; and Copenhagen Center for Translational Research (S.A., T.B.), Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pakkenberg</LastName><ForeName>Bente</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Research Laboratory for Stereology and Neuroscience (A.K.N., J.F., S.O., B.P., S.A., T.B.), and Department of Neurology (K.S., K.W.), Bispebjerg-Frederiksberg Hospital, University Hospital of Copenhagen; Neuromuscular Clinic (K.S.), Department of Neurology, Rigshospitalet, Copenhagen; Institute of Clinical Medicine (B.P.), Faculty of Health and Medical Sciences, University of Copenhagen; and Copenhagen Center for Translational Research (S.A., T.B.), Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aznar</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Research Laboratory for Stereology and Neuroscience (A.K.N., J.F., S.O., B.P., S.A., T.B.), and Department of Neurology (K.S., K.W.), Bispebjerg-Frederiksberg Hospital, University Hospital of Copenhagen; Neuromuscular Clinic (K.S.), Department of Neurology, Rigshospitalet, Copenhagen; Institute of Clinical Medicine (B.P.), Faculty of Health and Medical Sciences, University of Copenhagen; and Copenhagen Center for Translational Research (S.A., T.B.), Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brudek</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Research Laboratory for Stereology and Neuroscience (A.K.N., J.F., S.O., B.P., S.A., T.B.), and Department of Neurology (K.S., K.W.), Bispebjerg-Frederiksberg Hospital, University Hospital of Copenhagen; Neuromuscular Clinic (K.S.), Department of Neurology, Rigshospitalet, Copenhagen; Institute of Clinical Medicine (B.P.), Faculty of Health and Medical Sciences, University of Copenhagen; and Copenhagen Center for Translational Research (S.A., T.B.), Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark. tomasz.brudek@regionh.dk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA><NlmUniqueID>101636388</NlmUniqueID><ISSNLinking>2332-7812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>28</Day><Hour>11</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33361387</ArticleId><ArticleId IdType="pmc">PMC7768943</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000937</ArticleId><ArticleId IdType="pii">8/2/e937</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Redler RL, Dokholyan NV. Progress in molecular biology and translational science. Prog Mol Biol Transl 2012;107:215&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605887</ArticleId><ArticleId IdType="pubmed">22482452</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009;65:S3&#x2013;S9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19191304</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y, Tan CF, Onodera O, et al. . Sporadic amyotrophic lateral sclerosis: two pathological patterns shown by analysis of distribution of TDP-43-immunoreactive neuronal and glial cytoplasmic inclusions. Acta Neuropathol 2008;116:169.</Citation><ArticleIdList><ArticleId IdType="pubmed">18481073</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Lee V, Trojanowski JQ. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. Neuropathology 2010;30:103&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131978</ArticleId><ArticleId IdType="pubmed">20102519</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, et al. . Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 2009;117:137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloh RH. TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. FEBS J 2011;278:3539&#x2013;3549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177991</ArticleId><ArticleId IdType="pubmed">21777387</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Bigio EH, Ince PG, et al. . Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007;61:427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. . Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-based biomarker for ALS and FTLD. Mol Neurobiol 2018;55:7789&#x2013;7801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132775</ArticleId><ArticleId IdType="pubmed">29460270</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Kawakami E, Endo K, Misawa H, Watabe K. Formation and spreading of TDP-43 aggregates in cultured neuronal and glial cells demonstrated by time-lapse imaging. PLoS One 2017;12:e0179375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5466347</ArticleId><ArticleId IdType="pubmed">28599005</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, Eid L, Parent M, et al. . Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain 2016;139:3187&#x2013;3201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5840881</ArticleId><ArticleId IdType="pubmed">27679482</ArticleId></ArticleIdList></Reference><Reference><Citation>Avrameas S, Alexopoulos H, Moutsopoulos HM. Natural autoantibodies: an undersugn hero of the immune system and autoimmune disorders&#x2014;a point of view. Front Immunol 2018;9:1320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6005843</ArticleId><ArticleId IdType="pubmed">29946320</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagele EP, Han M, Acharya NK, DeMarshall C, Kosciuk MC, Nagele RG. Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One 2013;8:e60726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617628</ArticleId><ArticleId IdType="pubmed">23589757</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz HU. Homeostatic roles of naturally occurring antibodies: an overview. J Autoimmun 2007;29:287&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">17826952</ArticleId></ArticleIdList></Reference><Reference><Citation>Neff F, Wei X, N&#xf6;lker C, Bacher M, Du Y, Dodel R. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev 2008;7:501&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">18558370</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodel R, Balakrishnan K, Keyvani K, et al. . Naturally occurring autoantibodies against &#x3b2;-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci 2011;31:5847&#x2013;5854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622820</ArticleId><ArticleId IdType="pubmed">21490226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wootla B, Watzlawik JO, Warrington AE. Naturally occurring monoclonal antibodies and their therapeutic potential for neurologic diseases. JAMA Neurol 2015;72;1346&#x2013;1353.</Citation><ArticleIdList><ArticleId IdType="pubmed">26389734</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008;26:513&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">18370923</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddur MS, Kaveri SV, Bayry J. Circulating normal IgG as stimulator of regulatory T cells: lessons from intravenous immunoglobulin. Trends Immunol 2017;38:789&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">28916232</ArticleId></ArticleIdList></Reference><Reference><Citation>Strait RT, Posgai MT, Mahler A, et al. . IgG1 protects against renal disease in a mouse model of cryoglobulinaemia. Nature 2015;517:501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342786</ArticleId><ArticleId IdType="pubmed">25363774</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspina A, Puentes F, Amor S. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. Int Immunol 2015;27:117&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">25344935</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2009;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawilowsky SS. New effect size rules of thumb. J Mod Appl Stat Methods 2009;8:597&#x2013;599.</Citation></Reference><Reference><Citation>Brudek T, Winge K, Folke J, et al. . Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies. Mol Neurodegener 2017;12:44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5463400</ArticleId><ArticleId IdType="pubmed">28592329</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott KM, Kouli A, Yeoh SL, Clatworthy MR, Williams-Gray CH. A rystematic review and meta-analysis of alpha synuclein auto-antibodies in Parkinson's disease. Front Neurol 2018;9:815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6176114</ArticleId><ArticleId IdType="pubmed">30333787</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorothee G, Bottlaender M, Moukari E. Distinct patterns of antiamyloid-beta antibodies in typical and atypical Alzheimer disease. Arch Neurol 2012;69;1181&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pubmed">22710357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartos A, Fialov&#xe1; L, &#x160;varcov&#xe1; J. Lower serum antibodies against tau protein and heavy neurofilament in Alzheimer's disease. J Alzheimers Dis 2018;64:751&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">29966192</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Li L. Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications. J Biomed Res 2016;30:361&#x2013;372</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5044708</ArticleId><ArticleId IdType="pubmed">27476881</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddur MS, Lacroix-Desmazes S, Dimitrov JD, Kazatchkine MD, Bayry J, Kaveri SV. Natural antibodies: from first-line defense against pathogens to perpetual immune homeostasis. Clin Rev Allergy Immunol 2020;58:213&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">31161341</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Powell SZ, Appel JW, Arumanayagam AS, Rivera AL, Appel SH. Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis. Acta Neuropathologica Commun 2018;6:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899326</ArticleId><ArticleId IdType="pubmed">29653597</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogler TO, Wheeler JR, Nguyen ED, et al. . TDP-43 and RNA form amyloid-like myo-granules in regenerating muscle. Nature 2018;563:508&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324568</ArticleId><ArticleId IdType="pubmed">30464263</ArticleId></ArticleIdList></Reference><Reference><Citation>Han M, Nagele E, DeMarshall C, Acharya N, Nagele R. Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera. PLoS One 2012;7:e32383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285212</ArticleId><ArticleId IdType="pubmed">22384236</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagele E, Han M, DeMarshall C, Belinka B, Nagele R. Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One 2011;6:e23112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149629</ArticleId><ArticleId IdType="pubmed">21826230</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins AM, Jackson KJL. A temporal model of human IgE and IgG antibody function. Front Immunol 2013;4:235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3738878</ArticleId><ArticleId IdType="pubmed">23950757</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009;39:469&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">19222496</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014;5:520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4202688</ArticleId><ArticleId IdType="pubmed">25368619</ArticleId></ArticleIdList></Reference><Reference><Citation>Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 2008;63:1455&#x2013;1463.</Citation><ArticleIdList><ArticleId IdType="pubmed">18925882</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Veen W, Akdis M. Role of IgG4 in IgE-mediated allergic responses. J Allergy Clin Immunol 2016;138:1434&#x2013;1435.</Citation><ArticleIdList><ArticleId IdType="pubmed">27566454</ArticleId></ArticleIdList></Reference><Reference><Citation>Trampert DC, Hubers LM, van de Graaf SFJ, Beuers U. On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease. Biochim Biophys Acta Mol Basis Dis 2018;1864:1401&#x2013;1409.</Citation><ArticleIdList><ArticleId IdType="pubmed">28782655</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosroshahi A, Wallace ZS, Crowe JL, et al. . International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015;67:1688&#x2013;1699.</Citation><ArticleIdList><ArticleId IdType="pubmed">25809420</ArticleId></ArticleIdList></Reference><Reference><Citation>Folke J, Rydbirk R, L&#xf8;kkegaard A, et al. . Distinct autoimmune anti-&#x3b1;-synuclein antibody patterns in Multiple System Atrophy and Parkinson's disease. Front Immunol 2019;10:2253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6769034</ArticleId><ArticleId IdType="pubmed">31616427</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LF, Mo YQ, Ma JD, Luo L, Zheng D, Dai L. Elevated serum IgG4 defines specific clinical phenotype of rheumatoid arthritis. Mediators Inflamm 2014;2014:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4273547</ArticleId><ArticleId IdType="pubmed">25548435</ArticleId></ArticleIdList></Reference><Reference><Citation>Crescioli S, Correa I, Karagiannis P, et al. . IgG4 characteristics and functions in cancer immunity. Curr Allergy Asthma Rep 2016;16:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4705142</ArticleId><ArticleId IdType="pubmed">26742760</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh IA, Zesiewicz T, Xie Y, et al. . Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression. J Neuroimmunol 2009;215:96&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">19682755</ArticleId></ArticleIdList></Reference><Reference><Citation>Provinciali L, Laurenzi MA, Vesprini L, et al. . Immunity assessment in the early stages of amyotrophic lateral sclerosis: a study of virus antibodies and lymphocyte subsets. Acta Neurol Scand 1988;78:449&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">3265563</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolski S, Nikoli&#x107; J, Bugarski-Prokopljevi&#x107; C, Mileti&#x107; V, Pavlovi&#x107; S, Filipovi&#x107; S. Serum and CSF immunological findings in ALS. Acta Neurol Scand 1991;83:96&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">2017904</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Feng W, Huang R, et al. . Evidence for peripheral immune activation in amyotrophic lateral sclerosis. J Neurol Sci 2014;347:90&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">25312013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartfeld H, Dham C, Donnenfeld H, et al. . Immunological profile of amyotrophic lateral sclerosis patients and their cell-mediated immune responses to viral and CNS antigens. Clin Exp Immunol 1982;48:137&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1536567</ArticleId><ArticleId IdType="pubmed">6282508</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Evangelopoulos E, Sereti E, et al. . Alterations of T cell subsets in ALS: a systemic immune activation? T cell subsets in ALS. Acta Neurol Scand 2011;125:260&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">21651502</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Park YB, Patel E, Silverman GJ. IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J Immunol 2009;182:6031&#x2013;6043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428684</ArticleId><ArticleId IdType="pubmed">19414754</ArticleId></ArticleIdList></Reference><Reference><Citation>Tachovsky TG, Koprowski H, Lisak RP, Theofilopoulos AN, Dixon FJ. Circulating immune complexes in multiple sclerosis and other neurological diseases. Lancet 1976;308:997&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">62267</ArticleId></ArticleIdList></Reference><Reference><Citation>Noronha ABC, Antel JP, Roos RP, Medof ME. Circulating immune complexes in neurologic disease. Neurology 1981;31:1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">7198188</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasseau A, Boudigou M, Pottier LL, et al. . Innate B cells: the archetype of protective immune cells. Clin Rev Allergy Immunol 2019;58:92&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">31183788</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo PI. Role of natural autoantibodies and natural IgM anti-leucocyte autoantibodies in health and disease. Front Immunol 2016;7:198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893492</ArticleId><ArticleId IdType="pubmed">27375614</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 1999;169:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker LA, Schr&#xf6;der CD, Es van MA, Westers P, Visser-Meily JMA, Berg van den LH. Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model. J Neurol 2017;264:1413&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5502060</ArticleId><ArticleId IdType="pubmed">28608303</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol 2017;74:1446&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson MP, Staff NP, Bornschlegl S, et al. . Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PLoS One 2017;12:e0182002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersone L, Edner NM, Ovcinnikovs V, et al. . T cell/B cell collaboration and autoimmunity: an intimate relationship. Front Immunol 2018;9:1941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119692</ArticleId><ArticleId IdType="pubmed">30210496</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S, Garbelli S, Pasini A, et al. . Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J Neuroimmunol 2009;210:73&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">19307024</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, et al. . Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med 2013;5:64&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, et al. . ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight 2017;2:e89530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Gascon R, Miller RG, et al. . Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 2005;159:215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">15652422</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>